Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.
Level 5 - mechanism / opinion, no new human data
Narrative and historical review without systematic literature search or original clinical data
PubMed 16412534 · doi:10.1016/j.peptides.2005.01.029
What was done
This narrative and historical review outlines the design, synthesis, and clinical development milestones of synthetic melanocortin peptide analogs, focusing on melanotan I, melanotan II, and the derivative analog PT-141 for dermatological and sexual dysfunction indications.
What was found
The abstract reports no numerical data, sample sizes, or effect sizes. It qualitatively describes that melanotan I has been tested clinically for skin tanning, melanotan II has been tested for male erectile dysfunction, and PT-141 completed phase I/II trials and was scheduled for phase III trials for male and female sexual dysfunction.
Why it matters
The paper outlines the translational pathway of superpotent melanocortin receptor agonists from bench chemistry toward clinical therapeutics for photoprotection and sexual functionality.
Limits
As a narrative review, it presents no primary clinical trial datasets, statistical analyses, or safety and tolerability metrics. Findings are descriptive and subject to narrative selection bias.
Cited by
- supports Bremelanotide (PT-141) is a derivative of Melanotan II available as a prescription medication that provides sexual function benefits without skin tanning.